The Association of G9a Protein and the Outcome of Patients With Cervical Cancer

Cervical Cancer Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01505751
• Other study ID #: 100078-E
• Status: Completed
• Phase: N/A
• First received: December 27, 2011
• Last updated: September 4, 2016
• Start date: February 2012
• Est. completion date: February 2015

Study information

• Verified date: July 2015
• Source: Far Eastern Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 99 Years

Eligibility

Inclusion Criteria:

• cases with cervical cancer

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Locations

Country	Name	City	State
Taiwan	Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital	Banqiao	New Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Far Eastern Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer		From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months	No
Secondary	determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer		From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months	No